NVCR News and Press, NovoCure Limited From 12/27/22

Novocure (NASDAQ: NVCR) announced today it will participate in the 41 st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on January 1...

The jolly fellow with a white beard and a red-and-white suit doesn't just bring presents to children. He sometimes delivers gifts to investors, too. Years ago, investors observed that a phenomenon dubbed the Santa Claus rally often occurred during the year-end holidays. In many cases, stocks ...

Stock prices have been all over the place in 2022, making it a rather scary year for investors . The S&P 500 , which closed 2021 with 27% gains, is down 22% so far this year, as of this writing. It'll be an absolute stunner if the index can end 2022 in the green. Yet, December bri...

Optune is the first treatment for glioblastoma approved in Canada in over 12 years Novocure is actively working to secure reimbursement of Optune to make the therapy accessible for glioblastoma patients Novocure (NASDAQ: NVCR) today announced that Health Canada has a...

Many companies like to claim that they have revolutionary, game-changing products. Few live up to the hype. Novocure (NASDAQ: NVCR) could be an exception. Its tumor-treating fields (TTFields) therapy uses electrical signals to disrupt the division of tumor cells. But just be...

Novocure (NASDAQ: NVCR) announced today it will participate in the 34 th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside c...

Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population The largest safety dataset to date of more than 23,000 patients reinforced that TTField...

Novocure chose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. No...

New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, design...

Some investors prefer boring stocks. That's completely understandable. Boring stocks often deliver the best long-term returns. They're like the tortoise in Aesop's classic fable about the hare and the tortoise. But other investors seek more excitement. They know that hares win plenty of...